JNJ 53718678

Drug Profile

JNJ 53718678

Alternative Names: JNJ-678; JNJ-8678; JNJ53718678

Latest Information Update: 13 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Sciences Ireland UC
  • Developer Janssen Research & Development; Janssen Sciences Ireland UC
  • Class Antivirals; Small molecules
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 06 Feb 2018 Phase-II clinical trials in Respiratory syncytial virus infections in Sweden, USA (PO) (NCT03379675) (EudraCT2017-003252-24)
  • 20 Dec 2017 Janssen Research & Development plans a phase II trial for Respiratory syncytial virus in the US, Argentina, Australia, Belgium, Bulgaria, Canada, France, Germany, South Korea, Mexico, Poland, Russia, South Africa, Spain, Sweden, Taiwan and Ukraine (NCT03379675) (EudraCT2017-003252-24)
  • 10 Nov 2017 Janssen terminates a phase I trial in Respiratory syncytial virus infections (In infants) in USA, Australia, Argentina, Brazil, Netherlands, Philippines, Belgium, Spain and Sweden due to unavailability of clinical supplies (PO) (NCT02593851)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top